SciBrunch Therapeutics recently announced the completion of an angel round financing of over RMB 200 million. The round was co-led by BioTrack Capital and HanKang Capital, with participation from Elikon Venture and LongRiver Investments. The proceeds will mainly be used for preclinical and early clinical development of the company’s existing pipeline.

SciBrunch is a research-driven biotechnology company focused on iterative innovation of small-molecule oncology drugs. The company explores clinically validated targets from a new perspective, conducts forward-looking differentiated product design, and builds a globally competitive product pipeline.

The company was co-founded by Dr. Hu Tao, a seasoned serial entrepreneur, and Dr. Zhang Yang, a medicinal chemistry expert. With more than 20 years of professional experience at renowned global and domestic pharmaceutical companies including Merck, Amgen, and WuXi AppTec, Dr. Hu Tao has built multi-dimensional expertise in innovative drug R&D, business development, and corporate governance. Prior to founding SciBrunch, Dr. Hu served as Co-Founder and CEO of Usynova, a biotech company, and successfully led the global exclusive licensing of the preclinical oncology program UA022 to AstraZeneca in 2023.

Dr. Zhang Yang has nearly 20 years of experience in small-molecule innovative drug R&D and previously served as Vice President of the Domestic Drug Discovery Services Division at WuXi AppTec. Nearly 20 small-molecule oncology innovative drugs designed under his leadership are in various stages of clinical development, and multiple drug candidates have been licensed to overseas pharmaceutical and biotechnology companies.